Compare BCHT & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BCHT | ENTX |
|---|---|---|
| Founded | N/A | 2010 |
| Country | United States | Israel |
| Employees | 15 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.0M | 62.6M |
| IPO Year | 2026 | 2015 |
| Metric | BCHT | ENTX |
|---|---|---|
| Price | $1.40 | $1.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $15.00 | $9.00 |
| AVG Volume (30 Days) | ★ 183.2K | 124.9K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.25 |
| Revenue | N/A | ★ $42,000.00 |
| Revenue This Year | $13.42 | N/A |
| Revenue Next Year | $61.22 | N/A |
| P/E Ratio | ★ N/A | $5.44 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.29 | $0.91 |
| 52 Week High | $2.45 | $3.22 |
| Indicator | BCHT | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 29.53 | 55.67 |
| Support Level | N/A | $1.12 |
| Resistance Level | $1.74 | $1.38 |
| Average True Range (ATR) | 0.14 | 0.10 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 15.69 | 76.67 |
Birchtech Corp is a provider of specialty activated carbon technologies, delivering solutions for air and water purification. It provides patented and proprietary Sorbent Enhancement Additive (SEA) technologies for mercury emissions capture to the coal-fired utility sector, and is developing water purification technologies with a specialization on forever chemicals such as PFAS and PFOS. Geographically, the company derives all of its revenue from the United States.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.